Scholar Rock's apitegromab approved for SMA, not for GLP-1 muscle loss

The FDA approved ISEMBYLD (apitegromab-mstn) on September 11, 2026 for adults and children 2 years and older with spinal muscular atrophy (SMA) who are already receiving an SMN2-targeted treatment ^[2]. An industry pipeline report dated September 7, 2026 had listed the drug's US regulatory action date as September 30, 2026, following a Complete Response Letter in September 2025 that concerned the third-party facility handling fill-finish operations rather than apitegromab itself ^[1]. No European or Japanese decision dates have been reported ^[1][2].

The approval does not cover weight management or muscle preservation during GLP-1 treatment. That use remains investigational.

What the approval is based on

The decision rests on the Phase 3 SAPPHIRE study, in which people receiving apitegromab at 10 mg/kg plus an SMN2-targeted treatment improved by 2.2 points on the Hammersmith Functional Motor Scale-Expanded after one year, while those on an SMN2-targeted treatment alone lost motor function (nominal p = 0.0121; main efficacy population ages 2 to 12, n = 103) ^[2]. In the same trial, 34.2 percent of apitegromab-treated patients gained at least 3 points on that scale versus 13.5 percent on placebo (odds ratio 3.8; nominal p = 0.0125) ^[2].

Scholar Rock said its safety database covers more than 500 people across apitegromab studies, some treated for more than seven years, and that 98 percent of SAPPHIRE participants chose to continue into a long-term extension study ^[2]. The most common adverse reactions listed were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis and hypersensitivity. Fractures occurred in 9 percent of patients on the 10 mg/kg dose compared with 2 percent on placebo, and the label warns that fractures may happen with or without a fall or other injury ^[2].

What the obesity data show

The muscle-preservation interest in apitegromab comes from a different trial. In the Phase 2 EMBRAZE study, apitegromab was combined with tirzepatide, the molecule in Mounjaro and Zepbound, in 102 participants over 24 weeks. The combination produced 54.9 percent greater relative lean-mass retention than tirzepatide plus placebo, and the results were published in Nature Medicine in June ^[1].

Apitegromab is one of at least four programs targeting the myostatin-activin axis for muscle preservation during GLP-1 treatment. In the Phase 2b BELIEVE trial, 507 participants were enrolled across nine arms; the highest-dose combination of bimagrumab and semaglutide produced 22.1 percent total body weight loss at 72 weeks versus 15.7 percent for semaglutide alone, with lean-mass loss of 2.9 percent versus 7.4 percent ^[1]. Regeneron's COURAGE trial, testing trevogrumab with or without garetosmab, is expected to complete in late 2026, and Biohaven's taldefgrobep is in proof-of-concept testing with topline data expected in the second half of 2026 ^[1].

Why it matters for patients

No medication is approved to protect muscle mass during GLP-1 treatment. EMBRAZE was a Phase 2 study of 102 people followed for 24 weeks, and a filing for a muscle-preservation indication is described in the pipeline report as more plausibly some years away than months ^[1]. That report also states that resistance exercise and adequate protein intake remain the only evidence-supported interventions available today ^[1].

The safety information behind apitegromab's approval comes from people with SMA, a rare disease causing progressive muscle wasting ^[2]. How that profile, including the fracture signal, would apply to otherwise healthy adults taking a GLP-1 for weight loss has not been reported.

Access is also specific to the approved use. Scholar Rock says it is working with commercial and government payers on coverage for the SMA indication and has set up a patient support program for insurance questions, financial assistance and infusion logistics ^[2]. Whether any future muscle-preservation use would be covered has not been disclosed.

What happens next

Scholar Rock said the product would be available to ship in the coming days and hosted an investor call on September 14, 2026 ^[2]. The company received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a future marketing application ^[2]. Trial results that could shape any muscle-preservation filing are expected from Regeneron's COURAGE study in late 2026 and from Biohaven's taldefgrobep study in the second half of 2026 ^[1]. No date has been reported for a regulatory submission of apitegromab alongside a GLP-1 medication.